Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ashley Centner"'
Autor:
Natalie Lipari, Ashley Centner, John Glinski, Sophie Cohen, Fredric P. Manfredsson, Christopher Bishop
Publikováno v:
Neurobiology of Disease, Vol 176, Iss , Pp 105965- (2023)
Parkinson's disease associated psychosis (PDAP) is a prevalent non-motor symptom (NMS) that significantly erodes patients' and caregivers' quality of life yet remains vastly understudied. One potential source of PDAP in late-stage Parkinson's disease
Externí odkaz:
https://doaj.org/article/4f0f879ca8a64e74b7fc8c1574aded7e
Autor:
Carla Budrow, Kayla Elder, Michael Coyle, Ashley Centner, Natalie Lipari, Sophie Cohen, John Glinski, N’Senga Kinzonzi, Emily Wheelis, Grace McManus, Fredric Manfredsson, Christopher Bishop
Publikováno v:
Cells, Vol 12, Iss 6, p 837 (2023)
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor symptoms that result from loss of nigrostriatal dopamine (DA) cells. While L-DOPA provides symptom alleviation, its chronic use often results in the development of L-DO
Externí odkaz:
https://doaj.org/article/874e04ed7cf0486c9e0cdb0bba160b35
Autor:
Samantha Smith, Jordan Sergio, Michael Coyle, Kayla Elder, Ashley Centner, Sophie Cohen, Michelle Terry, Natalie Lipari, John Glinski, Emily Wheelis, Carla Budrow, Christopher Bishop
Publikováno v:
Psychopharmacology. 239:2119-2132
Parkinson's disease is a neurodegenerative disease often characterized by motor deficits and most commonly treated with dopamine replacement therapy. Despite its benefits, chronic use of L-DOPA results in abnormal involuntary movements known as L-DOP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b905b1bb659cb25b81a2ad40b909820a
https://doi.org/10.1007/s00213-022-06078-9
https://doi.org/10.1007/s00213-022-06078-9
Autor:
Natalie Lipari, Ashley Centner, John Glinski, Sophie Cohen, Fredric P. Manfredsson, Christopher Bishop
Publikováno v:
Neurobiology of disease. 176
Parkinson's disease associated psychosis (PDAP) is a prevalent non-motor symptom (NMS) that significantly erodes patients' and caregivers' quality of life yet remains vastly understudied. One potential source of PDAP in late-stage Parkinson's disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df491e9615016a909049c175ed0c0dcc
https://pubmed.ncbi.nlm.nih.gov/36526089
https://pubmed.ncbi.nlm.nih.gov/36526089
Publikováno v:
Brain Research. 1811:148381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3de36609381c7c63f0aaaeab33a80714
https://doi.org/10.1016/j.brainres.2023.148381
https://doi.org/10.1016/j.brainres.2023.148381
Autor:
Michael F. Salvatore, Ella A. Kasanga, D. Parker Kelley, Katy E. Venable, Tamara R. McInnis, Mark A. Cantu, Jennifer Terrebonne, Kathryn Lanza, Samantha M. Meadows, Ashley Centner, Christopher Bishop, Donald K. Ingram
Publikováno v:
GeroScience
Identifying neurobiological mechanisms of aging-related parkinsonism, and lifestyle interventions that mitigate them, remain critical knowledge gaps. No aging study, from rodent to human, has reported loss of any dopamine (DA) signaling marker near t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b96e615ff2726f336f819d96a59ec0d
https://pubmed.ncbi.nlm.nih.gov/35635679
https://pubmed.ncbi.nlm.nih.gov/35635679
Autor:
Sophie R. Cohen, Michelle L. Terry, Michael Coyle, Emily Wheelis, Ashley Centner, Samantha Smith, John Glinski, Natalie Lipari, Carla Budrow, Fredric P. Manfredsson, Christopher Bishop
Publikováno v:
Pharmacology Biochemistry and Behavior. 217:173393
Parkinson's disease (PD) is a progressive, neurodegenerative movement disorder caused by loss of nigrostriatal dopamine (DA) neurons. DA replacement therapy using L-3,4-dihydroxyphenylalanine (l-DOPA) improves motor function but often results in l-DO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d359a5b62e68e83025937c5befad47
https://doi.org/10.1016/j.pbb.2022.173393
https://doi.org/10.1016/j.pbb.2022.173393
Autor:
Fredric P. Manfredsson, Michael Coyle, Christopher Bishop, Isabella Del Priore, Kathryn Lanza, Ashley Centner
Publikováno v:
Experimental neurology. 336
Parkinson's Disease (PD) is symptomatically managed with L-DOPA but chronic use results in L-DOPA-induced dyskinesia (LID) characterized by abnormal involuntary movements (AIMs). In LID, dopamine D3 receptors (D3R) are upregulated on D1 receptor (D1R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c26bf6d9a8c0e1824388cc620386048
https://pubmed.ncbi.nlm.nih.gov/33249031
https://pubmed.ncbi.nlm.nih.gov/33249031